Now that Danish pharmaceutical company Novo Nordisk has an approval from the US Food and Drug Administration (FDA) in place, Novo Nordisk is ready to launch the obesity drug Wegovy on the US market in late June.
The company is already present on the obesity market with the drug Saxenda. It expects that the new product, which uses semaglutide as an injection-based treatment, will increase sales and give Novo Nordisk access to this unexploited market.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
Clinical Trial Manager - Genmab 
Radiochemist in CMC Development - Y-mAbs Therapeutics 
Drug Safety Advisor - ALK 
eTMF Manager - Klifo 
Senior Clinical Development Scientist/Physician - Lundbeck 
(Senior) Regulatory Science Specialist - IWA Consulting 
Associate Formulation Scientist, Oral Formulation Research - Novo Nordisk 
Employee for regulatory department 
Regulatory affairs life cycle specialist